A study of Lanabecestat (LY3314814) in Early Alzheimer’s Disease Dementia

Study identifier:16557

ClinicalTrials.gov identifier:NCT02972658

EudraCT identifier:2016-003440-36

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer’s Disease Dementia (Extension of Study AZES, The AMARANTH Study)

Medical condition

Alzheimer's disease

Phase

Phase 3

Healthy volunteers

No

Study drug

Lanabecestat

Sex

All

Actual Enrollment

421

Study type

Interventional

Age

55 Years +

Date

Study Start Date: 15 Mar 2017
Primary Completion Date: 02 Oct 2018
Study Completion Date: 02 Oct 2018

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2019 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Eli Lilly and Company

Inclusion and exclusion criteria